TY - JOUR T1 - Trimethoprim-sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant <em>Staphylococcus aureus</em> infections JF - Evidence Based Medicine JO - Evid Based Med SP - 140 LP - 140 DO - 10.1136/ebmed-2015-110241 VL - 20 IS - 4 AU - Stephan Harbarth Y1 - 2015/08/01 UR - http://ebm.bmj.com/content/20/4/140.abstract N2 - Commentary on: Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin-resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015;350:h2219.Despite decreasing incidence in many countries, severe infections caused by methicillin-resistant Staphylococcus aureus (S aureus, MRSA) continue to pose therapeutic challenges. Most MRSA strains remain susceptible to older antimicrobial agents such as trimethoprim-sulfamethoxazole (TMP-SMX);1 however, few randomised trials have evaluated its efficacy compared to current standard treatment options (vancomycin, daptomycin, linezolid).2 ,3 A single randomised controlled trial conducted more than two decades ago suggested that TMP-SMX may be a useful alternative to vancomycin for treatment of severe S aureus infections.4 This clinical trial examined whether TMP-SMX is non-inferior compared with vancomycin, for the treatment of … ER -